Literature DB >> 28454244

Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine.

Minoru Tomizawa1, Fuminobu Shinozaki2, Yasufumi Motoyoshi3, Takao Sugiyama4, Shigenori Yamamoto5, Naoki Ishige6.   

Abstract

Resistance to sorafenib in hepatocellular carcinoma (HCC) cells exhibiting stemness was evaluated using a sphere formation assay. A hepatocyte selection medium (HSM) deficient in glucose and arginine was used to suppress the proliferation of cell spheres composed of HLF and PLC/PRF/5 HCC cells, which were subjected to a sphere formation assay. Cell spheres were cultured with sorafenib and subjected to a cell proliferation assay and the expression levels of cytochrome P450 (CYP3A4) were analyzed in RNA extracted from sphere-forming cells using reverse transcription-quantitative polymerase chain reaction. Sphere-forming PLC/PRF/5 cells were more resistant to sorafenib, as compared with control cells, exhibiting higher expression levels of CYP3A4. When cultured in HSM, suppressed proliferation was observed in the sphere-forming PLC/PRF/5 cells and in the control cells, with no significant variation between them. The results suggest that deprivation of glucose and arginine is a potential novel treatment for HCC.

Entities:  

Keywords:  arginine; cytochrome P450; glucose; sorafenib; sphere formation assay

Year:  2017        PMID: 28454244      PMCID: PMC5403635          DOI: 10.3892/ol.2017.5565

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Hepatic gluconeogenic capacity from various precursors in young versus old rats.

Authors:  Ken D Sumida; Suzanne C Crandall; Puja L Chadha; Tauseef Qureshi
Journal:  Metabolism       Date:  2002-07       Impact factor: 8.694

Review 2.  Galactokinase: structure, function and role in type II galactosemia.

Authors:  H M Holden; J B Thoden; D J Timson; R J Reece
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

3.  Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.

Authors:  Hiroyuki Okuyama; Masafumi Ikeda; Akiko Kuwahara; Hideaki Takahashi; Izumi Ohno; Satoshi Shimizu; Shuichi Mitsunaga; Shoichi Senda; Takuji Okusaka
Journal:  Oncology       Date:  2014-12-11       Impact factor: 2.935

4.  The Warburg effect: a balance of flux analysis.

Authors:  B Vaitheesvaran; J Xu; J Yee; Lu Q-Y; V L Go; G G Xiao; W N Lee
Journal:  Metabolomics       Date:  2015-08       Impact factor: 4.290

5.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

6.  Role of pyruvate in ischaemia-like conditions on cultured neurons.

Authors:  K Matsumoto; K Yamada; E Kohmura; A Kinoshita; T Hayakawa
Journal:  Neurol Res       Date:  1994-12       Impact factor: 2.448

7.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Authors:  Junji Furuse; Hiroshi Ishii; Kohei Nakachi; Eiichiro Suzuki; Satoshi Shimizu; Keiko Nakajima
Journal:  Cancer Sci       Date:  2007-10-22       Impact factor: 6.716

Review 8.  Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Authors:  Melissa M Phillips; Michael T Sheaff; Peter W Szlosarek
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

9.  Studies on primary cultures of differentiated fetal liver cells.

Authors:  H L Leffert; D Paul
Journal:  J Cell Biol       Date:  1972-03       Impact factor: 10.539

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  1 in total

1.  Downregulation of Rab27A contributes to metformin-induced suppression of breast cancer stem cells.

Authors:  Feixue Feng; Jianping Zhang; Xiaoxuan Fan; Fang Yuan; Yinghao Jiang; Ruihua Lv; Yanxia Ma
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.